SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications (SYTHROM)

Clinical Trial ID NCT04539678

Rank	Title	Journal	Year	PubWeight™‹?›
1	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.	Blood	2008	2.21
2	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.	Blood	2009	2.11
3	Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	J Clin Oncol	2011	1.88
4	Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).	Blood	2012	1.77
5	Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia.	Lancet	1978	1.52
6	Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.	J Thromb Haemost	2007	1.28